Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509-Reference-Cited by-同舟云学术

Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

Published:2011-11 Issue:11 Volume:6 Page:1938-1945
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Garland Linda L.,Chansky Kari,Wozniak Antoinette J.,Tsao Anne S.,Gadgeel Shirish M.,Verschraegen Claire F.,DaSilva Marco A.,Redman Mary,Gandara David R.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. Latent period for malignant mesothelioma of occupational origin;Lanphear;J Occup Med,1992

2. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005;Price;Crit Rev Toxicol,2009

3. The European mesothelioma epidemic;Peto;Br J Cancer,1999

4. Malignant mesothelioma;Kao;Intern Med J,2010

5. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050;Hodgson;Br J Cancer,2005

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials;PLOS ONE;2023-12-21

2. Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM);Clinical Lung Cancer;2023-09

3. Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins;Frontiers in Oncology;2023-05-25

4. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?;International Journal of Molecular Sciences;2023-05-23

5. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma;Current Oncology Reports;2022-06-03